Evidence map›Paper›PMID 27657810›Full record

ArticleEuropean journal of medicinal chemistry2017

Tetracyclic indolines as a novel class of β-lactam-selective resistance-modifying agent for MRSA.

Yugen Zhu, Lakota Cleaver, Wei Wang, Jessica D Podoll, Shane Walls, Austin Jolly, Xiang Wang

Abstract read
In one paragraph

Article in European journal of medicinal chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Zn(OTf)Chemical science · 2019
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yugen ZhuDepartment of Chemistry and Biochemistry, University of Colorado, Boulder, CO 80309, USA.
Lakota CleaverDepartment of Chemistry and Biochemistry, University of Colorado, Boulder, CO 80309, USA.
Wei WangDepartment of Chemistry and Biochemistry, University of Colorado, Boulder, CO 80309, USA.
Jessica D PodollDepartment of Chemistry and Biochemistry, University of Colorado, Boulder, CO 80309, USA.
Shane WallsDepartment of Chemistry and Biochemistry, University of Colorado, Boulder, CO 80309, USA.
Austin JollyDepartment of Chemistry and Biochemistry, University of Colorado, Boulder, CO 80309, USA.
Xiang WangDepartment of Chemistry and Biochemistry, University of Colorado, Boulder, CO 80309, USA. Electronic address: xiang.wang@colorado.edu.
University of Colorado Boulder · US

Funding

Development of Novel Resistance-Modifying Agents for MRSAR33AI121581 · NIAID · UNIVERSITY OF COLORADO · PI WANG, XIANG · 2018 to 2020
$1.4M
Development of Novel Resistance-Modifying Agents for MRSAR21AI121581 · NIAID · UNIVERSITY OF COLORADO · PI WANG, XIANG · 2016 to 2017
$411k
NIAID NIH HHS R21 AI121581NIAID NIH HHS R33 AI121581
6 · The paper itself

Abstract

Antibiotic-resistant bacterial infections have seen a marked increase in recent years, while antibiotic discovery has waned. Resistance-modifying agents (RMA) offer an intriguing alternative strategy to fight against resistant bacteria. Here we report the discovery, antibiotic profiling, and structure-activity relationships of a novel class of RMAs, tetracyclic indolines. These selectively potentiate β-lactam antibiotics in methicillin-resistant Staphylococcus aureus (MRSA) without antibacterial or β-lactamase inhibitory activity on their own. The most potent analogue, 6a, showed strong potentiation of amoxicillin/clavulanic acid in a variety of hospital-acquired and community-acquired MRSA strains with low mammalian toxicity. These compounds may be further developed to extend the clinic life span of β-lactam antibiotics.

Indexed as

AnimalsAnti-Bacterial Agentsbeta-LactamsCommunity-Acquired InfectionsDrug Resistance, BacterialDrug SynergismHumansIndolesMethicillin-Resistant Staphylococcus aureusStructure-Activity RelationshipTetracyclinesAnti-Bacterial Agentsbeta-LactamsIndolesindolineTetracyclinesAntibiotic resistanceIndoline alkaloidsMethicillin-resistant Staphylococcus aureusResistance-modifying agentStructure-activity relationshipβ-lactam

Identifiers

PMID27657810
PMCPMC5148702
OpenAlexW2519533100

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.